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Abstract
Background: MicroRNAs (miRNAs) are a class of non-coding regulatory RNAs of ~22 nucleotides in length. miRNAs
regulate gene expression post-transcriptionally, primarily by associating with the 3’ untranslated region (UTR) of
their regulatory target mRNAs. Recent work has begun to reveal roles for miRNAs in a wide range of biological
processes, including cell proliferation, differentiation and apoptosis. Many miRNAs are expressed in cardiac and
skeletal muscle, and dysregulated miRNA expression has been correlated with muscle-related disorders. We have
previously reported that the expression of muscle-specific miR-1 and miR-133 is induced during skeletal muscle
differentiation and miR-1 and miR-133 play central regulatory roles in myoblast proliferation and differentiation in
vitro.
Methods: In this study, we measured the expression of miRNAs in the skeletal muscle of mdx mice, an animal
model for human muscular dystrophy. We also generated transgenic mice to overexpress miR-133a in skeletal
muscle.
Results: We examined the expression of miRNAs in the skeletal muscle of mdx mice. We found that the expression
of muscle miRNAs, including miR-1a, miR-133a and miR-206, was up-regulated in the skeletal muscle of mdx mice.
In order to further investigate the function of miR-133a in skeletal muscle in vivo, we have created several
independent transgenic founder lines. Surprisingly, skeletal muscle development and function appear to be
unaffected in miR-133a transgenic mice.
Conclusions: Our results indicate that miR-133a is dispensable for the normal development and function of
skeletal muscle.
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Background
MicroRNAs (miRNAs) are a class of ~ 22 nt non-coding
RNAs that regulate gene expression post-transcription-
ally [1-3]. The involvement of miRNAs in muscle biol-
ogy has recently been reported [4-11]. miRNAs regulate
the expression of transcription factors and signaling
mediators important for cardiac and skeletal muscle
development and function [7,12-14]. Aberrant miRNA
expression has been observed in muscle diseases, includ-
ing cardiac and skeletal muscle hypertrophy, heart fail-
ure and muscular dystrophy [13,15-17].
A subset of miRNAs, miR-1, miR-133, miR-206 and
miR-208, are either specifically or highly expressed in
cardiac and skeletal muscle and are called myomiRs
[6,7,13]. Among them, miR-133 was shown to promote
the proliferation of myoblasts and inhibits their differen-
tiation in cultured skeletal muscle myoblasts. miR-133
enhances myocyte proliferation, at least in part, by redu-
cing protein levels of SRF, a crucial regulator for muscle
differentiation [18,19]. miR-133 also inhibits the transla-
tion of polypyrimidine tract-binding protein (nPTB),
which controls differential transcript splicing during ske-
letal-muscle differentiation [20]. Paradoxically, miR-1
and miR-133 exert opposing effects to skeletal-muscle
development despite originating from the same miRNA
polycistronic transcript. Interestingly, miR-1 and miR-
133 also produce opposing effects on apoptosis [21].
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towards cardiomyocytes is promoted by miR-1 and
inhibited by miR-133 [22]. Furthermore, miR-1 and
miR-133 are also important regulators of cardiomyocyte
differentiation and heart development [22-24].
Primary skeletal-muscle disorders involve different
groups of diseases, including muscular dystrophies,
inflammatory myopathies and congenital myopathies.
Although the number of genes that are involved in mus-
cle disorders increases every year and histological
pathology of disease tissue is well documented, the
underlying molecular pathways remain poorly under-
stood [25]. Recent studies have begun to link miRNAs
to certain muscle-related diseases [6,13,15,26,27]. In a
recent report, comprehensive miRNA expression profil-
ing revealed that a total of 185 miRNAs were dysregu-
lated in samples of diseased muscle tissue from 10
different muscle disorders. Five miRNAs (miR-146b,
miR-221, miR-155, miR-214 and miR-222) were consis-
tently regulated in almost all samples that were exam-
ined [15], suggesting a possible involvement of common
miRNA-mediated regulatory mechanisms in muscle dis-
orders. In addition to those studies of miRNA expres-
sion on muscle disorders, a direct genetic link has
connected miRNA function to muscular hypertrophy
[28]. A mutation that is responsible for the exceptional
muscularity of Texel sheep has been mapped to a single
G-to-A mutation within the 3’ UTR of the mRNA
encoding myostatin, a member of the transforming
growth factor-b (TGFb) family, which functions to
repress muscle growth. This mutation creates a binding
site for miR-1 and miR-206, leading to the translational
repression of myostatin, which phenocopies the “muscle
doubling” that results from the loss of myostatin in
mice, cattle, and humans [29,30]. These findings under-
score the importance of miRNA-mediated regulation in
diverse muscle biological processes and disease status.
In this study, we attempted to determine the function
of miR-133 in skeletal muscle. We employed a gain-of-
function approach and generated transgenic mice to
overexpress miR-133a-1 in skeletal muscle, using the
well-characterized muscle creatine kinase (MCK) pro-
moter. Surprisingly, we found that miR-133a-1 trans-
genic mice appear to be normal. Additional analyses
indicated that skeletal muscle development and function
were not altered in miR-133a-1 transgenic mice. Our
study therefore suggests that miR-133a is dispensable
for skeletal muscle development.
Methods
Mice
The mdx mice which carry a point mutation in the dys-
trophin gene were obtained from the Jackson Lab [31].
Skeletal muscle was collected from the hind legs of 1
month old mdx and control mice for RNA extraction.
In order to generate miR-133a-1 transgenic mice, a
genomic fragment encoding the precursor and franking
sequences of the miR-133a-1 gene, which is located on
mouse chromosome 18, was amplified by PCR using
mouse genomic DNA as a template. The primers used
for amplification are: miR-133a-1F: 5’ AAGCTAGC-
GAATTCCATGTGACCCCTCACACACA 3’;m i R -
133a-1R: 5’ TTCTCGAGACAAGGGGAGCCTG-
GATCCC 3’. Underlined nucleotide sequences are
added adaptors for restriction enzyme digestion. The
same primers were used for genotyping of transgenic
mice.
The DNA fragment was cloned into a transgenic vec-
tor plasmid driving by a muscle-specific muscle creatine
kinase (MCK) promoter [32]. The miR-133a-1 trans-
genic construct was injected into the pronuclei of C57/
Bl6 X C3H hybrid embryos and implanted into pseudo-
pregnant recipient females by the University of North
Carolina Animal Models Core. Five positive founder
lines were obtained.
Ethics Statement
All animal procedures were approved by and performed
in accordance with the University of North Carolina
Institutional Animal Care and Use Committee under the
protocol 08-227.0.
Northern Blot and RT-PCR Analysis
Taqman-based miRNA quantitative RT-PCR (Applied
Biosystems) was performed as described [33] using total
RNAs isolated from skeletal muscle of 1 month old mdx
and the control mice (n = 4). MicroRNA Northern blot
analyses were performed as described previously [8,18].
Briefly, 20 μg of total RNAs isolated from skeletal mus-
cle of 1 month old mdx and the control mice (Figure 1),
or from the heart, skeletal muscle and liver tissues of
miR-133a-1 transgenic and the control mice (Figure 2),
were used and miRNA oligonucleotides with corre-
sponding miRNAs (miR-1a, miR-133a and miR-206)
sequences were used as probes. qRT-PCR was repeated
three times and Northern blots were performed two
times on skeletal muscle of four mice per genotype
tested.
Histological and immunohistochemistry analyses
Histological processing and immunohistochemistry
staining of skeletal muscle tissues were performed as
described previously [8,34]. Samples were stained with
Hematoxylin and Eosin (H&E) for routine examination.
Laminin conjugated staining was applied to identify sar-
colemmal membranes so that myofiber diameter could
be directly visualized. Histological and immunohisto-
chemistry analyses were performed on least 4 animals
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were acquired by a camera (UFX-DX; Nikon) mounted
on an inverted (TE2000, Nikon) or an upright fluores-
cence microscope (Microphot-SA; Nikon). Digital fluor-
escent images were captured at room temperature and
the images were processed using SPOT (version 3.5.4
for MacOS; Diagnostic Instruments) software and were
scaled down and cropped in Photoshop (Adobe) to pre-
pare the final figures. Gel images were quantified using
the Photoshop Histogram Analysis and was plotted
using Microsoft excel and is shown as relative expres-
sion level after normalized by controls.
Results
Changed expression of muscle miRNAs in the skeletal
muscle of mdx mice
Mdx mice harbor a spontaneous mutation in the dystro-
phin gene [31]. The skeletal muscle of the mdx mice is
histologically normal early in postnatal development, but
starting around 3 weeks muscle necrosis develops with
some visible muscle weakness. Therefore, mdx mice
have been widely used as an animal model to study the
skeletal muscle degeneration/regeneration process
[35-37]. We examined miRNA expression in the skeletal
muscle of mdx mice. We found that the expression
levels of miR-1, miR-133 and miR-206 were higher in
the skeletal muscle of one month-old mdx mice (Figure
1A). Northern blot analyses further confirmed a signifi-
cantly increased expression of miR-206, whereas the
expression of miR-1 modestly increased in the muscle
muscle of mdx mice (Figure 1B, C). These data indicate
that these muscle miRNAs might be involved in the reg-
ulation of skeletal muscle degeneration and/or
regeneration.
Transgenic overexpression of miR-133a-1 in the skeletal
muscle
Recently, miR-133 genes (miR-133a-1 and miR-133a-2)
were knocked out from the mouse genome. Analysis of
mice that lost either miR-133a-1 or miR-133a-2 revealed
that both miRNAs are dispensable for development or
Figure 1 Increased expression of muscle miRNAs in the
skeletal muscle of mdx mice. (A) Fold change of the expression of
indicated miRNAs in the skeletal muscle of 1 month old mdx mice
(n = 3) as detected by qRT-PCR analyses. Statistical differences were
determined using the Student’s t-test; (*) P < 0.05. (B) Northern blot
analyses of the expression of miR-1 and miR-206 in the skeletal
muscle of mdx and the wild type control mice (n = 3). Precursors
and mature miRNAs are indicated. tRNAs were used as a loading
control. (C) The intensity of mature miRNA products from Northern
blot was quantified using the Photoshop Histogram Analysis and
was plotted using Microsoft excel and is shown as relative
expression level after normalized by tRNA. Statistical differences
were determined using the Student’s t-test; (*) P < 0.05.
Figure 2 Generation of miR-133a transgenic mice. (A) Diagram
of transgenic construct used in this study to overexpress miR-133a
in the skeletal muscle of transgenic mice. Two arrows represent PCR
primers used for genotyping. MCK: muscle creatine kinase; hGH:
human growth hormone. (B) PCR genotyping of miR-133a
transgenic founder mice. * indicated genotyping positive founder
lines; M: DNA size marker; +: Positive control; -: Negative control. (C)
Northern blot analyses of miR-133a expression in the heart, skeletal
muscle and liver tissues of the wild type and transgenic mice. tRNAs
were used as a loading control. (D) The intensity of skeletal muscle
expressed miR-133a from Northern blot was quantified using the
Photoshop Histogram Analysis and was plotted using Microsoft
excel and is shown as relative expression level after normalized by
tRNA. Statistical differences were determined using the Student’s
t-test; (*) P < 0.05.
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ever, double knockout mice display defects in the heart
[24]. In order to further investigate the function of miR-
133 in vivo, we took a gain-of-function approach and
generated transgenic mice to overexpress miR-133a-1 in
skeletal muscle. We used the well-characterized muscle
creatine kinase (MCK) promoter to drive miR-133a-1
expression in skeletal muscle (and to a less extend, car-
diac muscle). Genomic DNA from mouse chromosome
18 encoding the miR-133a-1 gene was inserted into an
expression vector (Figure 2A). The MCK-miR-133a-1
transgenic construct was injected into fertilized mouse
eggs and multiple transgenic founder lines were
obtained, as verified by PCR genotyping (Figure 2B).
The overexpression of miR-133a-1 in germline-trans-
mitted stable transgenic mice was confirmed by North-
ern blot analyses. Total RNAs were isolated from
indicated tissues, and the overexpression of miR-133a-1
was clearly detected in the skeletal muscle, and to a
much less extent, the cardiac muscle, but not in the
liver of transgenic mice (Figure 2C, D).
Normal skeletal muscle development in miR-133
transgenic mice
All miR-133a-1 transgenic mice were viable and fertile
without overt abnormality (Figure 3A, B). The body
weight and size between wild type and miR-133a-1
transgenic adult mice (ages from 2 to 12 months) were
indistinguishable (n = 40, data not shown). There was
not difference in skeletal muscle formation or body fat
deposit between miR-133a-1 transgenic mice and their
littermate controls (Figure 3C, D). Because the MCK
promoter also directed miR-133a-1 overexpression in
the heart, albeit at lower level, we determined whether
heart development was affected in the transgenic mice.
However, our results showed that there was no differ-
ence in the gross morphology of the adult hearts of
miR-133a-1 transgenic mice and wild type controls (Fig-
ure 3E, F).
In order to further analyze muscle development, skele-
tal muscle from the diaphragms of six month old miR-
133a-1 transgenic mice was collected and examined by
tissue histology (n = 4). As shown in Figure 4, hematox-
ylin and eosin (H&E) staining of diaphragms indicated
that the tissue thickness, muscle cell size and numbers
were comparable between miR-133a-1 transgenic mice
and the control wild type mice. It is noticeable that
there is a slight increase in the vesicles in the transgenic
diaphragm (Figure 4, arrows).
Similarly, we examined the skeletal muscle of the
extensor digitorum longus (EDL) from six month old of
both miR-133a-1 transgenic and wild type control mice
(n = 4). H&E staining suggested that there was no dif-
f e r e n c ei ns k e l e t a lm u s c l em o r p h o l o g yb e t w e e nm i R -
133a-1 transgenic mice and their control littermates
(Figure 5A). Immunohistochemistry using an antibody
that specifically recognizes laminin, a structural and bio-
logically active component in basement membranes
which labels the cell membrane, confirmed that the size
a n dm o r p h o l o g yo fs k e l e t a lm u s c l ei nt r a n s g e n i cm i c e
were indistinguishable from that of controls (Figure 5B).
Together, these data suggest that miR-133a is dispensa-
ble for the normal development and function of skeletal
muscle.
Discussion
In this study, we investigated the function of miR-133a
in skeletal muscle. We found that the expression miR-
133a, together with that of miR-206 and miR-1a, was
induced in the skeletal muscle of mdx mice. However,
transgenic overexpression of miR-133a-1 in skeletal
muscle did not result in a noticeable change in skeletal
muscle development and morphogenesis. Our results
are consistent with a recent report in which miR-133
loss-of-function mice did not induce overt defects in
skeletal muscle [24].
It is known that many miRNAs are tissue-specifically
expressed. Among them, miR-1, miR-133, miR-206,
miR-208 and miR-499 have been described as muscle
specific miRNAs, or myomiRs [6,13]. In addition to
their muscle specific expression in normal physiological
condition, the expression of some of those myomiRs
was shown to be dynamically regulated in pathological
and/or diseased muscles. For example, miR-206 levels
are elevated in the diaphragm muscle of the mdx
mouse, an animal model of muscular dystrophy [27].
Furthermore, miR-1 and miR-206 also participate the
regulation of skeletal muscle satellite cell proliferation
and differentiation [8]. Both gain- and loss-of-function
Figure 3 Normal cardiac and skeletal muscle development in
miR-133a transgenic mice. (A-B) The gross morphology of a 6-
month old miR-133a transgenic (Tg) mouse is normal and
indistinguishable from its wild type (Wt) littermate (n = 4). (C-D)
Representative de-skined mice show normal skeletal muscle
morphology in miR-133a transgenic mice (Tg) when compared with
the wild type littermate (Wt). (E-F) The heart of miR-133a transgenic
mouse (Tg) is indistinguishable from that of the wild type (Wt)
littermate.
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those muscle miRNAs [10,23,34,38-41]. Interestingly,
gene targeting of some of the myomiRs demonstrated
that they are dispensable for the normal development
and function of cardiac and skeletal muscles [10,40].
However, many of those miRNAs are indispensable for
stress-responsive muscle remodeling. Recently, we
reported that overexpression of miR-208a in the heart,
which is normally restricted to cardiac tissue, was suffi-
cient to induce cardiac hypertrophy in transgenic mice
[34]. However, in the current study, we did not observe
any overt muscle defect in mice expressing the MCK-
miR-133a-1 transgene. This may suggest that cardiac
and skeletal muscle have adapted distinct requirement
for miRNAs for tissue homeostasis.
Given the vast number of miRNAs and the diverse
functions in different biological processes observed in
the relatively small number of miRNAs studied thus far,
it is apparent that many new and unanticipated func-
tions of miRNAs in normal muscle development, func-
tion and disorders are waiting to be discovered.
Considering that many miRNAs fine-tune gene-expres-
sion programs and the intrinsic complexity of miRNA
functional models [42,43], it will important in the future
to systematically analyze the potential function of miR-
NAs in both gain- and loss-of-function animal models.
Conclusions
In this study, we demonstrate that miR-133a is dispen-
sable for the normal development and function of skele-
tal muscle.
Acknowledgements
We thank members of the Wang and Deng laboratories for discussion and
support and Dr. John Mably for critical reading of the manuscript. This work
was supported by the March of Dimes Birth Defect Foundation, National
Institutes of Health and Muscular Dystrophy Association. Z Deng is
supported by the Chinese National Natural Science Foundation # 30772211.
DZ Wang is an Established Investigator of the American Heart Association.
Author details
1Department of Orthopaedic Surgery, The Second Affiliated Hospital,
Chongqing Medical University, Chongqing 400010, P.R.China.
2McAllister
Heart Institute, University of North Carolina, Chapel Hill, NC 27599-7126, USA.
3Department of Cardiology, Children’s Hospital Boston, Harvard Medical
School, 320 Longwood Avenue, Boston, MA 02115, USA.
Figure 4 Histology of skeletal muscle from diaphragm of wild
type and miR-133a transgenic mice. Hematoxylin and eosin (H&E)
staining for skeletal muscle tissue sections of diaphragm from 6
month old wild type (Wt) and miR-133a transgenic mice (MCK-miR-
133). Black arrows point to vesicles found in the muscle of
transgenic mice.
Figure 5 Histology of skeletal muscle from wild type and miR-
133a transgenic mice. (A) Hematoxylin and eosin (H&E) staining of
skeletal muscle tissue transverse sections of EDL (extensor digitorum
longus) muscle from 6 month old wild type (Wt) and miR-133a-1
transgenic mice (MCK-miR-133). (B) Immunohistology of skeletal
muscle tissue transverse sections of EDL (extensor digitorum longus)
muscle from 6 month old wild type (cont) and miR-133a-1
transgenic mice (MCK-miR-133). Laminin staining outlines muscle
cells. DAPI staining illustrates position of nuclei.
Deng et al. BMC Musculoskeletal Disorders 2011, 12:115
http://www.biomedcentral.com/1471-2474/12/115
Page 5 of 7Authors’ contributions
ZD and DZW designed the experiment; ZD and JFC performed experiments;
ZD and DZ. DZW analyzed the data and wrote the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2011 Accepted: 26 May 2011
Published: 26 May 2011
References
1. Ambros V: microRNAs: tiny regulators with great potential. Cell 2001,
107(7):823-826.
2. Ambros V: The functions of animal microRNAs. Nature 2004,
431(7006):350-355.
3. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell
2009, 136(2):215-233.
4. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A: Muscle-specific
microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006,
174(5):677-687.
5. Callis TE, Deng Z, Chen JF, Wang DZ: Muscling through the microRNA
world. Exp Biol Med (Maywood) 2008, 233(2):131-138.
6. Chen JF, Callis TE, Wang DZ: microRNAs and muscle disorders. J Cell Sci
2009, 122(Pt 1):13-20.
7. van Rooij E, Liu N, Olson EN: MicroRNAs flex their muscles. Trends Genet
2008, 24(4):159-166.
8. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ: microRNA-1 and
microRNA-206 regulate skeletal muscle satellite cell proliferation and
differentiation by repressing Pax7. J Cell Biol 190(5):867-879.
9. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF: Myogenic
factors that regulate expression of muscle-specific microRNAs. Proc Natl
Acad Sci USA 2006, 103(23):8721-8726.
10. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R,
Sanes JR, Olson EN: MicroRNA-206 delays ALS progression and promotes
regeneration of neuromuscular synapses in mice. Science 2009,
326(5959):1549-1554.
11. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ: MyoD
inhibits Fstl1 and Utrn expression by inducing transcription of miR-206.
J Cell Biol 2006, 175(1):77-85.
12. Callis TE, Wang DZ: Taking microRNAs to heart. Trends in molecular
medicine 2008, 14(6):254-260.
13. Williams AH, Liu N, van Rooij E, Olson EN: MicroRNA control of muscle
development and disease. Curr Opin Cell Biol 2009, 21(3):461-469.
14. Zhao Y, Srivastava D: A developmental view of microRNA function. Trends
Biochem Sci 2007, 32(4):189-197.
15. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG,
Kang PB, North KN, Mitrani-Rosenbaum S, et al: Distinctive patterns of
microRNA expression in primary muscular disorders. Proceedings of the
National Academy of Sciences of the United States of America 2007,
104(43):17016-17021.
16. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M,
Rojas M, Hammond SM, Wang DZ: Expression of microRNAs is
dynamically regulated during cardiomyocyte hypertrophy. Journal of
molecular and cellular cardiology 2007, 42(6):1137-1141.
17. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW,
Doevendans PA, Mummery CL, Borlak J, Haverich A, et al: MicroRNAs in the
human heart: a clue to fetal gene reprogramming in heart failure.
Circulation 2007, 116(3):258-267.
18. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM,
Conlon FL, Wang DZ: The role of microRNA-1 and microRNA-133 in
skeletal muscle proliferation and differentiation. Nat Genet 2006,
38(2):228-233.
19. Niu Z, Li A, Zhang SX, Schwartz RJ: Serum response factor micromanaging
cardiogenesis. Current opinion in cell biology 2007, 19(6):618-627.
20. Boutz PL, Chawla G, Stoilov P, Black DL: MicroRNAs regulate the
expression of the alternative splicing factor nPTB during muscle
development. Genes & development 2007, 21(1):71-84.
21. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B:
The muscle-specific microRNAs miR-1 and miR-133 produce opposing
effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in
cardiomyocytes. Journal of cell science 2007, 120(Pt 17):3045-3052.
22. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ,
Conklin BR, Bernstein HS, et al: MicroRNA regulation of cell lineages in
mouse and human embryonic stem cells. Cell stem cell 2008, 2(3):219-229.
23. Zhao Y, Ransom JF, Li A, Vedantham V, von M, Muth AN, Tsuchihashi T,
McManus MT, Schwartz RJ, Srivastava D: Dysregulation of cardiogenesis,
cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007,
129(2):303-317.
24. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R,
Olson EN: microRNA-133a regulates cardiomyocyte proliferation and
suppresses smooth muscle gene expression in the heart. Genes Dev 2008,
22(23):3242-3254.
25. Davies KE, Nowak KJ: Molecular mechanisms of muscular dystrophies: old
and new players. Nature reviews 2006, 7(10):762-773.
26. McCarthy JJ, Esser KA: MicroRNA-1 and microRNA-133a expression are
decreased during skeletal muscle hypertrophy. J Appl Physiol 2007,
102(1):306-313.
27. McCarthy JJ, Esser KA, Andrade FH: MicroRNA-206 is overexpressed in the
diaphragm but not the hindlimb muscle of mdx mouse. American journal
of physiology 2007, 293(1):C451-457.
28. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F,
Elsen JM, Eychenne F, et al: A mutation creating a potential illegitimate
microRNA target site in the myostatin gene affects muscularity in sheep.
Nature genetics 2006, 38(7):813-818.
29. Tobin JF, Celeste AJ: Myostatin, a negative regulator of muscle mass:
implications for muscle degenerative diseases. Current opinion in
pharmacology 2005, 5(3):328-332.
30. Lee SJ: Regulation of muscle mass by myostatin. Annual review of cell and
developmental biology 2004, 20:61-86.
31. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ: The
molecular basis of muscular dystrophy in the mdx mouse: a point
mutation. Science 1989, 244(4912):1578-1580.
32. Johnson JE, Wold BJ, Hauschka SD: Muscle creatine kinase sequence
elements regulating skeletal and cardiac muscle expression in
transgenic mice. Mol Cell Biol 1989, 9(8):3393-3399.
33. Huang ZP, Chen JF, Regan JN, Maguire CT, Tang RH, Dong XR, Majesky MW,
Wang DZ: Loss of microRNAs in neural crest leads to cardiovascular
syndromes resembling human congenital heart defects. Arterioscler
Thromb Vasc Biol 30(12):2575-2586.
34. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF,
Deng Z, Gunn B, Shumate J, et al: MicroRNA-208a is a regulator of cardiac
hypertrophy and conduction in mice. J Clin Invest 2009, 119(9):2772-2786.
35. De la Porte S, Morin S, Koenig J: Characteristics of skeletal muscle in mdx
mutant mice. Int Rev Cytol 1999, 191:99-148.
36. Messina S, Mazzeo A, Bitto A, Aguennouz M, Migliorato A, De Pasquale MG,
Minutoli L, Altavilla D, Zentilin L, Giacca M, et al: VEGF overexpression via
adeno-associated virus gene transfer promotes skeletal muscle
regeneration and enhances muscle function in mdx mice. FASEB J 2007,
21(13):3737-3746.
37. Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M,
Cardani R, Perbellini R, Isaia E, Sale P, et al: Common micro-RNA signature
in skeletal muscle damage and regeneration induced by Duchenne
muscular dystrophy and acute ischemia. FASEB J 2009, 23(10):3335-3346.
38. Zhao Y, Samal E, Srivastava D: Serum response factor regulates a muscle-
specific microRNA that targets Hand2 during cardiogenesis. Nature 2005,
436(7048):214-220.
39. Olson EN: Gene regulatory networks in the evolution and development
of the heart. Science 2006, 313(5795):1922-1927.
40. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN: Control of
stress-dependent cardiac growth and gene expression by a microRNA.
Science 2007, 316(5824):575-579.
41. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA,
Kelm RJ Jr, Olson EN: A family of microRNAs encoded by myosin genes
governs myosin expression and muscle performance. Dev Cell 2009,
17(5):662-673.
Deng et al. BMC Musculoskeletal Disorders 2011, 12:115
http://www.biomedcentral.com/1471-2474/12/115
Page 6 of 742. Ambros V: The evolution of our thinking about microRNAs. Nat Med
2008, 14(10):1036-1040.
43. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of
microRNAs on protein output. Nature 2008, 455(7209):64-71.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/12/115/prepub
doi:10.1186/1471-2474-12-115
Cite this article as: Deng et al.: Transgenic overexpression of miR-133a
in skeletal muscle. BMC Musculoskeletal Disorders 2011 12:115.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Deng et al. BMC Musculoskeletal Disorders 2011, 12:115
http://www.biomedcentral.com/1471-2474/12/115
Page 7 of 7